Patents by Inventor Aileen L. Pangan

Aileen L. Pangan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220281882
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-?]pyrrolo[2.3-]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: February 9, 2022
    Publication date: September 8, 2022
    Inventors: Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder, Aileen L. Pangan, Jaclyn Kay Anderson, In-Ho Song, Jose Jeffrey V. Enejosa
  • Publication number: 20220273651
    Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
    Type: Application
    Filed: April 28, 2022
    Publication date: September 1, 2022
    Applicant: AbbVie Inc.
    Inventors: Aileen L. Pangan, Roopal B. Thakkar, Steven Jungerwirth, Ana Paula Machado De Lacerda, Anne M. Robinson, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
  • Publication number: 20220233527
    Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
    Type: Application
    Filed: April 1, 2022
    Publication date: July 28, 2022
    Inventors: Ana Paula Machado De Lacerda, Jose Jeffrey V. Enejosa, Aileen L. Pangan, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
  • Patent number: 11365198
    Abstract: The present disclosure relates to pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and corresponding methods of treating psoriatic arthritis.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: June 21, 2022
    Assignee: AbbVie Inc.
    Inventors: Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Aileen L. Pangan, Jaclyn Kay Anderson
  • Publication number: 20210361647
    Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
    Type: Application
    Filed: December 9, 2020
    Publication date: November 25, 2021
    Inventors: Roopal B. Thakkar, Steven Jungerwirth, Ana Paula Machado de Lacerda, Ann M. Robinson, Jose Jeffrey V. Enejosa, Aileen L. Pangan, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klunder, Ayman D. Allian
  • Publication number: 20210228575
    Abstract: Provided are methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis (PsO), with the JAK1 inhibitor, upadacitinib free base or pharmaceutically acceptable salt thereof. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA), methods for treating active ankylosing spondylitis (AS), methods for treating active psoriatic arthritis (PsA), and methods for treating active psoriasis (PsO).
    Type: Application
    Filed: September 30, 2020
    Publication date: July 29, 2021
    Inventors: Aileen L. Pangan, Jaclyn Kay Anderson, In-Ho Song, Jose Jeffrey V. Enejosa
  • Patent number: 10995095
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: May 4, 2021
    Assignee: AbbVie Inc.
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
  • Publication number: 20200385393
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: December 19, 2019
    Publication date: December 10, 2020
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Ayman D. Allian, Thomas B. Borchardt, Jayanthy Jayanth, Patrick J. Marroum, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Peter T. Mayer, Ben KLÜNDER
  • Patent number: 10597400
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: March 24, 2020
    Assignee: AbbVie Inc.
    Inventors: Ahmed A. Othman, Mohamed-Eslam F. Mohamed, Ben Klünder, Aileen L. Pangan
  • Patent number: 10550126
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-?]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: February 4, 2020
    Assignee: AbbVie Inc.
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
  • Publication number: 20190322677
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: July 1, 2019
    Publication date: October 24, 2019
    Inventors: Ahmed A. OTHMAN, Mohamed-Eslam F. MOHAMED, Ben KLÜNDER, Ayman ALLIAN, Aileen L. PANGAN
  • Publication number: 20190046527
    Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
    Type: Application
    Filed: March 9, 2018
    Publication date: February 14, 2019
    Inventors: Roopal B. THAKKAR, Steven JUNGERWIRTH, Ana Paula Machado de LACERDA, Anne M. ROBINSON, Jose Jeffrey V. ENEJOSA, Aileen L. PANGAN, Mohamed-Eslam F. MOHAMED, Ahmed A. OTHMAN, Ben KLÜNDER
  • Publication number: 20180298016
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: April 16, 2018
    Publication date: October 18, 2018
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Ayman D. Allian, Thomas B. Borchardt, Jayanthy Jayanth, Patrick J. Marroum, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Peter T. Mayer